摘要
目的:评估鸡Ⅱ型胶原(chicken collagen typeⅡ,CCⅡ)对大鼠骨关节炎(osteoarthritis,OA)的防治效果。方法:参照Hayami的方法诱导大鼠OA模型。免疫组化法原位测定基质金属蛋白酶13及组织蛋白酶K水平,比较灌胃高剂量(80μg/d)与低剂量(20μg/d)CCⅡ及对照药布洛芬(10 mg/d)对大鼠OA模型关节软骨的形态学及生化改变的影响。实验分预防性研究与治疗性研究,预防性研究组,术后当日开始用药;治疗性研究组,从术后第7周开始用药;治疗时间均为8周。结果:治疗性灌胃CCⅡ不能完全阻止,但可显著延缓大鼠OA软骨降解,并能降低基质金属蛋白酶13和组织蛋白酶K水平,但远未达到正常水平。预防性灌胃CCⅡ对延缓软骨降解、降低基质金属蛋白酶13和组织蛋白酶K水平的效果比治疗性用药更佳,但仍未达到正常水平。布洛芬对软骨降解及基质金属蛋白酶13和组织蛋白酶K水平无明显影响。结论:CCⅡ可能成为治疗OA的药物。
Objective： To evaluate the prophylactic and therapeutic effects of gavage chicken collagen type Ⅱ （CC Ⅱ ） on osteoarthritis in rats. Methods： Osteoarthritis model was surgically induced by method of Hayami. The levels of matrix metalloproteinase 13 and cathepsin K were examined by immunohistochemical method. The effects of CC Ⅱ at high dose（80 /μg/d）, low dose（20 /μg/d） and control medicine ibuprofen（10 mg/d） on the morphological and biochemical changes of articular cartilage in osteoarthritis rats were compared. The experiment was divided into prophylactic and therapeutic studies. In prophylactic groups, CC Ⅱ was given on the day of operation, while in therapeutic groups, administration of CC Ⅱ was begun on the seventh week after operation. The therapy period was 8 weeks. Results： In therapeutic groups, CC Ⅱ prevented articular cartilage from degradation and decreased the levels of matrix metalloproteinase 13 and eathepsin K obviously, but these indexes were still different obviously from those of normal group. In prophylactic groups, the efficacy of CC Ⅱ was better than that in therapeutic groups, but the levels of matrix metalloproteinase 13 and cathepsin K were still above the normal levels. Ibuprofen had no obvious effect on articular cartilage degradation and decreasing the levels of matrix metalloproteinase 13 and cathepsin K. Conclusion： CC Ⅱ may become a drug for osteoarthritis.
出处
《药学服务与研究》
CAS
CSCD
2005年第4期335-340,共6页
Pharmaceutical Care and Research
关键词
胶原Ⅱ型
骨关节炎
膝
基质金属蛋白酶
组织蛋白酶K
大鼠
collagen type Ⅱ
osteoarthritis,knee
matrix metalloproteinase
cathepsin K
cartilage, articular
